קארדוכסין אמפולות
rafa laboratories ltd - dipyridamole 10 mg / 2 ml - solution for injection - dipyridamole - as an alternative to exercise stress in thallium myocardial imaging, particularly in patients unable to exercise or in those for whom exercise may be contraindicated.
אפטיפיבאטיד טבע ® 2 מ"ג/מ"ל
teva pharmaceutical indust.ltd - eptifibatide 2 mg/ml - solution for injection - eptifibatide - eptifibatide teva is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty directional atheretomy transluminal extraction catheter atherectomy rotational ablation angioplasty or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death myorardial infarction need for urgent intervention). eptifibatide is intended for use with aspirin and heparin.
אגרסטט
tzamal bio-pharma ltd - tirofiban as hydrochloride monohydrate 0.25 mg/ml - solution for infusion - tirofiban - aggrastat in combination with heparin, is indicated for patients with unstable angina or non-q-wave myocardial infarction to prevent cardiac ischemic events and is also indicated for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing ptca or atherectomy. in this setting, aggrastat has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction or refractory ischemia/repeat cardiac procedure.
פרוטוזול
kamada ltd - aprotinin 10000 kiu / 1 ml - solution for injection - aprotinin - protosol is used in adults in the treatment and prophylaxis of disorders in which inhibition of proteolytic enzymes is indicated: for the early treatment of states of shock. for the prevention of postoperative or post-traumatic complications. to reduce major blood loss in patients undergoing surgery involving cardiopulmonary bypass.
תרומביקסיל
omrix biopharmaceuticals - calcium chloride 5.6 - 6.2 mg; human thrombin 800 - 1200 iu - solution - thrombin - as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standart surgical techniques is ineffective or impractical.
פרלסיט
sanofi - aventis israel ltd - ferrous gluconate as iron iii sodium ferric glugonate compl. 62.5 mg / 5 ml - solution for injection - various combinations - severe iron deficiency states only when oral administration has been found impossible in cases of gastrointestinal malabsorption which rules out oral iron therapy patients treated by dialysis getting erythropoietin.
פרלסיט
sanofi israel ltd - iron as iron iii sodium ferric glugonate compl. - solution for injection - iron as iron iii sodium ferric glugonate compl. 62.5 mg / 5 ml - various combinations - various combinations - severe iron deficiency states only when oral administration has been found impossible in cases of gastrointestinal malabsorption which rules out oral iron therapy patients treated by dialysis getting erythropoietin.
רקורמון 2000 iu
roche pharmaceuticals (israel) ltd - epoetin beta 2000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
רקורמון iu 3000
roche pharmaceuticals (israel) ltd - epoetin beta 3000 iu / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative
מירסרה 30 מק"ג/0.3 מ"ל
roche pharmaceuticals (israel) ltd - methoxy polyethylene glycol-epoetin beta 30 mcg/ml / 0.3 ml - solution for injection - erythropoietin - treatment of anemia associated with chronic kidney disease (ckd).